Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_assertion type Assertion NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_head.
- NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_provenance.
- NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_assertion evidence source_evidence_literature NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_provenance.
- NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_assertion SIO_000772 19679880 NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_provenance.
- NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_assertion wasDerivedFrom befree-2016 NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_provenance.
- NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_assertion wasGeneratedBy ECO_0000203 NP757509.RAzBevuG6PK7cTEpJzK6pfg86qGwCkNiumgvefeDOKNis130_provenance.